Porter, MA
Alyssa Porter, Norwell, MA US
Patent application number | Description | Published |
---|---|---|
20130157242 | GENERATING AND EVALUATING LEARNING ACTIVITIES FOR AN EDUCATIONAL ENVIRONMENT - An educational activity system allows a teacher to specify activity parameters, such as subject, grade level, and template format that define an activity for one or more students to complete on a computer. The system then uses the selected activity parameters to determine appropriate subject matter from a content asset database and generates an activity incorporating the determined appropriate subject matter. After a student completed the activity via a computer, the system evaluates the completed activity for correctness and stores the results of each student in a student performance database. | 06-20-2013 |
Barry Porter, Bridgewater, MA US
Patent application number | Description | Published |
---|---|---|
20100181347 | HANDHELD SPRAY RECEPTOR - The handheld spray receptor provides an apparatus which, when used with a supply of a liquid under pressure, dispenses a liquid material in a pattern that is controlled by an inexpensive and disposable actuator. Such actuators are employed as an industry standard part that would be found on any aerosol spray can, and feature small cylindrical actuators that may be easily interchanged, so as to provide varied spray patterns. A purging model provides for a quick and convenient method of purging liquid from the actuator, so as to prevent hardening of liquid material exposed to the atmosphere, and a subsequent clogging of the receptor. When used with a supply of liquid under pressure and access to a propellant, the handheld spray receptor significantly reduces the amount of hazardous waste, in the form of partially consumed aerosol cans, that would otherwise enter landfills or hazardous waste recycling facilities. | 07-22-2010 |
Barry W. Porter, Bridgewater, MA US
Patent application number | Description | Published |
---|---|---|
20090057436 | Portable Water-Based Paint Spray Apparatus and Method of Use - Disclosed is a portable water-based paint spray apparatus and method of using the same. Argon gas is preferably used both to charge the spray container with pressure and is also used to atomize the water-based paint at the spray receptor. | 03-05-2009 |
Bradley G. Porter, North Billerica, MA US
Patent application number | Description | Published |
---|---|---|
20120177376 | Conformal Hybrid EO/RF Aperture - A conformal hybrid elctro-optical/radio frequency (EO/RF) aperture including an optical phased array (OPA) in a center portion of the aperture, and a variable inclination continuous transverse stub (VICTS) RF antenna surrounding the OPA using a plurality of continuous transverse stub (CTS) subarrays. | 07-12-2012 |
Dale Porter, Boston, MA US
Patent application number | Description | Published |
---|---|---|
20100196891 | IBC-1 (Invasive Breast Cancer-1), a Putative Oncogene Amplified in Breast Cancer - This invention encompasses antibodies specific for IBC-1 (Invasive Breast Cancer-1), methods for diagnosis and prognosis of metastatic breast cancer and degenerative neural conditions, methods of identifying and manufacturing therapeutic compounds, and methods of treating patients with invasive and metastatic breast cancer or degenerative neural conditions. | 08-05-2010 |
20100273158 | HIN-1, A Tumor Suppressor Gene - The invention encompasses isolated DNAs encoding HIN-1 polypeptides, vectors containing such DNAs, cells containing the vectors, and isolated HIN-1 polypeptides. The invention also features methods of making and using HIN-1 polypeptides. | 10-28-2010 |
Dale Porter, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20150105434 | BIOMARKERS FOR IAP INHIBITOR THERAPY - A method of selecting a subject having cancer for treatment with an IAP inhibitor. | 04-16-2015 |
Dale A. Porter, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20120196793 | BIOMARKERS FOR IAP INHIBITOR COMPOUNDS - A method to predict which patients will respond to a IAP inhibiting compound comprising administering an IAP inhibitor compound to a patient/and measuring IL1B, Lymphotoxin alpha (LTa), TWEAK, LIGHT, Fas, TNF alpha or TRAIL levels. | 08-02-2012 |
Dale Alan Porter, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20100316573 | Organic Compounds - A method to predict which patients will respond to a IAP inhibiting compound comprising: | 12-16-2010 |
Gregory Alan Porter, Lawrence, MA US
Patent application number | Description | Published |
---|---|---|
20140305441 | Cushion for Crossed-Ankle and Other Body Part Support - A support and cushioning structure is disclosed. The support and cushioning structure is capable of supporting and cushioning the ankles in crossed-ankle positions. It includes a lower channel sized and positioned to allow a lower leg to pass through, and a top face with an elongate concave support for the calf of the upper leg and a symmetrical pair of concave ankle rests for the ankle of the upper leg. The support and cushioning structure may be comprised of a block of foam, such as urethane foam, and may be covered by a flexible cover. | 10-16-2014 |
James R. Porter, Brighton, MA US
Patent application number | Description | Published |
---|---|---|
20080269272 | CYCLOPAMINE ANALOGUES AND METHODS OF USE THEREOF - The present invention provides compositions and methods for modulating smoothened-dependent pathway activation. The present invention provides analogs of cyclopamine that can be used to counteract the phenotypic effects of unwanted activation of a hedgehog pathway, such as resulting from hedgehog gain-of-function, Ptc loss-of-function or smoothened gain-of-function mutations. The compounds of the present invention are particularly useful in treating cancers. | 10-30-2008 |
20110166353 | Cyclopamine Analogues and Methods of Use Thereof - The present invention provides compositions and methods for modulating smoothened-dependent pathway activation. The present invention provides analogs of cyclopamine that can be used to counteract the phenotypic effects of unwanted activation of a hedgehog pathway, such as resulting from hedgehog gain-of-function, Ptc loss-of-function or smoothened gain-of-function mutations. The compounds of the present invention are particularly useful in treating cancers. | 07-07-2011 |
Jeffery Porter, Lexington, MA US
Patent application number | Description | Published |
---|---|---|
20080207740 | Small organic molecule regulators of cell proliferation - The present invention makes available methods and reagents for modulating proliferation or differentiation in a cell or tissue comprising contacting the cell with a hedgehog agonist, such as the compounds depicted in FIGS. | 08-28-2008 |
Jeffery A. Porter, Lexington, MA US
Patent application number | Description | Published |
---|---|---|
20090054632 | Hydrophobically-modified protein compositions and methods - Hydrophobically-modified proteins and methods of making them are described. A hydrophobic moiety is attached to a surface amino acid residue of the protein. The hydrophobic moiety can be a lipid or a peptide. Alternatively, the protein can be derivatized by a wide variety of chemical reactions that append a hydrophobic structure to the protein. The preferred protein is of mammalian origin and is selected from the group consisting of Sonic, Indian, and Desert hedgehog. The hydrophobic moiety is used as a convenient tether to which may be attached a vesicle such as a cell membrane, liposome, or micelle. | 02-26-2009 |
Jeffrey Porter, Lexington, MA US
Patent application number | Description | Published |
---|---|---|
20100003256 | Use of TGF-Beta Antagonists in Treatment of Parathyroid-Related Disorders - The present invention relates to the use of TGF-β antagonists for the treatment, amelioration, and diagnosis of parathyroid-related disorders, e.g., HPT-JT, familial isolated primary hyperparathyroidism (FIPH), and hyperparathyroidism-jaw tumor (HPT-JT) syndrome, as well as its attendant complications. The present invention also relates to the use of modulators of HRPT2 and its related PAF1 complex for the treatment, amelioration, and diagnosis of TGFβ-related disorders, e.g., pulmonary hypertension, cancer, hypertension, fibrosis, wound healing. Assays of the identification of modulators of HRPT2/PAF1 and SMAD/TGFβ are also provided. | 01-07-2010 |
Jeffrey A. Porter, Belmont, MA US
Patent application number | Description | Published |
---|---|---|
20090186029 | Antibodies that specifically bind hedgehog-derived polypeptides - The present invention provides two novel polypeptides, referred to as the “N” and “C” fragments of hedgehog, or N-terminal and C-terminal fragments, respectively, which are derived after specific cleavage at a G′CF site recognized by the autoproteolytic domain in the native protein. Also included are sterol-modified hedgehog polypeptides and functional fragments thereof. Methods of identifying compositions which affect hedgehog activity based on inhibition of cholesterol modification of hedgehog protein are described. | 07-23-2009 |
20110002941 | Antibodies that Specifically Bind Hedgehog-Derived Polypeptides - The present invention provides two novel polypeptides, referred to as the “N” and “C” fragments of hedgehog, or N-terminal and C-terminal fragments, respectively, which are derived after specific cleavage at a G′CF site recognized by the autoproteolytic domain in the native protein. Also included are sterol-modified hedgehog polypeptides and functional fragments thereof. Methods of identifying compositions which affect hedgehog activity based on inhibition of cholesterol modification of hedgehog protein are described. | 01-06-2011 |
20120183603 | INHIBITORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED THERETO - The present invention makes availables assays and reagents inhibiting paracrine and/or autocrine signals produced by a hedgehog protein or aberrant activation of a hedgehog signal transduction pathway, e.g., which involve the use of a steroidal alkaloid or other small molecule. | 07-19-2012 |
Jeffrey A. Porter, Lexington, MA US
Patent application number | Description | Published |
---|---|---|
20100273818 | INHIBITORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED THERETO - The present invention makes availables assays and reagents inhibiting paracrine and/or autocrine signals produced by a hedgehog protein or aberrant activation of a hedgehog signal transduction pathway, e.g., which involve the use of a steroidal alkaloid or other small molecule. | 10-28-2010 |
20120171779 | ANTIBODIES THAT SPECIFICALLY BIND HEDGEHOG-DERIVED POLYPEPTIDES - The present invention provides two novel polypeptides, referred to as the “N” and “C” fragments of hedgehog, or N-terminal and C-terminal fragments, respectively, which are derived after specific cleavage at a G′ CF site recognized by the autoproteolytic domain in the native protein. Also included are sterol-modified hedgehog polypeptides and functional fragments thereof. Methods of identifying compositions which affect hedgehog activity based on inhibition of cholesterol modification of hedgehog protein are described. | 07-05-2012 |
Jonathan Porter, Manchester, MA US
Patent application number | Description | Published |
---|---|---|
20150127358 | CARE TRACKER - Methods and apparatus for facilitating coordination of care. A method of transmitting care coordination data to a healthcare provider associated with a patient based, at least in part, on a proximity of the patient to a healthcare facility may involve determining, with at least one processor, whether the proximity of the patient to the healthcare facility satisfies a criterion. The method may further involve transmitting the care coordination data to the healthcare provider associated with the patient after it is determined that the proximity of the patient to the healthcare facility satisfies the criterion. | 05-07-2015 |
Tyrone M. Porter, Boston, MA US
Patent application number | Description | Published |
---|---|---|
20080199957 | ENHANCED TRANSPORT USING MEMBRANE DISRUPTIVE AGENTS - Compositions and methods for transport or release of therapeutic and diagnostic agents or metabolites or other analytes from cells, compartments within cells, or through cell layers or barriers are described. The compositions include a membrane barrier transport enhancing agent and are usually administered in combination with an enhancer and/or exposure to stimuli to effect disruption or altered permeability, transport or release. In a preferred embodiment, the compositions include compounds which disrupt endosomal membranes in response to the low pH in the endosomes but which are relatively inactive toward cell membranes, coupled directly or indirectly to a therapeutic or diagnostic agent. Other disruptive agents can also be used, responsive to stimuli and/or enhancers other than pH, such as light, electrical stimuli, electromagnetic stimuli, ultrasound, temperature, or combinations thereof. The compounds can be coupled by ionic, covalent or H bonds to an agent to be delivered or to a ligand which forms a complex with the agent to be delivered. Agents to be delivered can be therapeutic and/or diagnostic agents. Treatments which enhance delivery such as ultrasound, iontophoresis, and/or electrophoresis can also be used with the disrupting agents. | 08-21-2008 |
20110288238 | ENHANCED TRANSPORT USING MEMBRANE DISRUPTIVE AGENTS - Compositions and methods for transport or release of therapeutic and diagnostic agents or metabolites or other analytes from cells, compartments within cells, or through cell layers or barriers are described. The compositions include a membrane barrier transport enhancing agent and are usually administered in combination with an enhancer and/or exposure to stimuli to effect disruption or altered permeability, transport or release. In a preferred embodiment, the compositions include compounds which disrupt endosomal membranes in response to the low pH in the endosomes but which are relatively inactive toward cell membranes, coupled directly or indirectly to a therapeutic or diagnostic agent. Other disruptive agents can also be used, responsive to stimuli and/or enhancers other than pH, such as light, electrical stimuli, electromagnetic stimuli, ultrasound, temperature, or combinations thereof. The compounds can be coupled by ionic, covalent or H bonds to an agent to be delivered or to a ligand which forms a complex with the agent to be delivered. Agents to be delivered can be therapeutic and/or diagnostic agents. Treatments which enhance delivery such as ultrasound, iontopheresis, and/or electrophoresis can also be used with the disrupting agents. | 11-24-2011 |
20140219950 | ENHANCED TRANSPORT USING MEMBRANE DISRUPTIVE AGENTS - Compositions and methods for transport or release of therapeutic and diagnostic agents or metabolites or other analytes from cells, compartments within cells, or through cell layers or barriers are described. The compositions include a membrane barrier transport enhancing agent and are usually administered in combination with an enhancer and/or exposure to stimuli to effect disruption or altered permeability, transport or release. In a preferred embodiment, the compositions include compounds which disrupt endosomal membranes in response to the low pH in the endosomes but which are relatively inactive toward cell membranes, coupled directly or indirectly to a therapeutic or diagnostic agent. Other disruptive agents can also be used, responsive to stimuli and/or enhancers other than pH, such as light, electrical stimuli, electromagnetic stimuli, ultrasound, temperature, or combinations thereof. The compounds can be coupled by ionic, covalent or H bonds to an agent to be delivered or to a ligand which forms a complex with the agent to be delivered. Agents to be delivered can be therapeutic and/or diagnostic agents. Treatments which enhance delivery such as ultrasound, iontophoresis, and/or electrophoresis can also be used with the disrupting agents. | 08-07-2014 |
Venda J. Porter, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20100025595 | Electro-optical device - An electro-optical device can include a plurality of nanocrystals positioned between a first electrode and a second electrode. | 02-04-2010 |
William Porter, Granby, MA US
Patent application number | Description | Published |
---|---|---|
20130254254 | SERVICE MEDIATION MODEL - Embodiments of the invention relate to processing service requests and responses using a service mediation model. A service transaction is received and one or more processing operations are performed on the service transaction. The one or more processing operations perform one or more operations on the service transaction based on requirements associated with a service consumer and a service provider associate with the service. The service transaction is transmitted once the processing operations are complete. | 09-26-2013 |